ArticleNeurochemical research2025
Identification of Novel Biomarkers Related to Vesicle Trafficking in Alzheimer's Disease Using Bioinformatics Approaches.
Article in Neurochemical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Decoding Pathogenic Mutational Landscapes in Alzheimer's Disease Through Integrated Transcriptomics.Human mutation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder with complex pathogenesis. Vesicle trafficking abnormalities are closely associated with AD, making the identification of related biomarkers crucial. Chip data of AD were downloaded from the GEO database as training and test sets. Differentially expressed vesicle trafficking-related genes were analyzed, followed by construction of protein-protein interaction (PPI) networks, machine learning for important biomarkers identification, and various analyses including ROC curve analysis, and construction of regulatory networks. A total of 149 differentially expressed vesicle trafficking-related genes were identified. Through multiple analyses, 5 key genes (KIF22, ACTR10, TUBB2A, TUBA3C, and DCTN1) were obtained. Additionally, potential miRNA regulatory networks and candidate drugs were predicted, and AD subtypes were characterized.This study successfully identified novel biomarkers related to vesicle trafficking in AD, and these findings provide new insights into the role of intracellular transport dysfunction in AD pathogenesis.
Indexed as
Identifiers
40338387What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.